Holen Sie sich die Stockscreener-App
7.74
0.32%
0.13
Schlusskurs vom Vortag:
$7.87
Offen:
$7.95
24-Stunden-Volumen:
10,001
Relative Volume:
0.13
Marktkapitalisierung:
$71.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.42M
KGV:
-1.3818
EPS:
-5.6013
Netto-Cashflow:
$-7.45M
1W Leistung:
+1.35%
1M Leistung:
-8.51%
6M Leistung:
+18.91%
1J Leistung:
+262.17%
1-Tages-Spanne:
$7.51
$8.00
1-Wochen-Bereich:
$7.35
$8.01
52-Wochen-Spanne:
$1.92
$16.94
Cervomed Inc Stock (CRVO) Company Profile
Firmenname
Cervomed Inc
Sektor
Branche
Telefon
(617) 744-4400
Adresse
20 PARK PLAZA, BOSTON
Vergleichen Sie CRVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
7.74 | 72.82M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.36 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-12-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-18 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-07-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
Will CervoMed Inc. stock deliver consistent dividends2025 Risk Factors & Fast Gain Swing Alerts - ulpravda.ru
Is CervoMed Inc. (DP8) stock overpriced at current multiples2025 Year in Review & Daily Market Momentum Tracking - ulpravda.ru
CervoMed Releases Updated Investor Presentation and Business Overview - TipRanks
Is CervoMed Inc. stock a dividend growth opportunityWeekly Trade Review & Long-Term Growth Stock Strategies - ulpravda.ru
Will CervoMed Inc. stock gain from strong economyGlobal Markets & High Win Rate Trade Tips - ulpravda.ru
Aug Weekly: Is CervoMed Inc stock vulnerable to regulatory risksTrade Analysis Summary & Growth Focused Stock Pick Reports - moha.gov.vn
Is CervoMed Inc DP8 a good long term investmentMarket Sentiment Report & Learn From the Strategies of Institutions - earlytimes.in
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Will CervoMed Inc. stock see insider buyingVolume Analysis Techniques & Small Entry Cost Portfolio - bollywoodhelpline.com
Can CervoMed Inc. stock rebound after recent weakness2025 Market Overview & Risk Controlled Swing Alerts - Улправда
Will CervoMed Inc. (DP8) stock return to pre crash levels2025 Trading Volume Trends & Technical Pattern Based Signals - Улправда
What analyst consensus says on CervoMed Inc. stockStock Surge & Verified High Yield Trade Plans - Улправда
Is CervoMed Inc. stock vulnerable to regulatory risksEarnings Miss & Technical Analysis for Trade Confirmation - DonanımHaber
Aug Patterns: Will CervoMed Inc. stock gain from strong economyProduct Launch & AI Based Buy and Sell Signals - DonanımHaber
Why CervoMed Inc. (DP8) stock attracts wealthy investorsStop Loss & Advanced Technical Signal Analysis - DonanımHaber
CervoMed (NASDAQ:CRVO) Receives Buy Rating from HC Wainwright - Defense World
Can CervoMed Inc. stock sustain institutional interest2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Cantor Fitzgerald initiates CervoMed stock with Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald Initiates Coverage on CervoMed (CRVO) with Ove - GuruFocus
HC Wainwright Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO) - MarketBeat
Cantor Fitzgerald Initiates Coverage on CervoMed With Overweight Rating - marketscreener.com
Cantor Fitzgerald initiates CervoMed stock with Overweight rating - Investing.com India
CervoMed Earnings Notes - Trefis
CEO Change: Is CervoMed Inc DP8 stock supported by strong fundamentals2025 Trading Volume Trends & Technical Pattern Based Signals - moha.gov.vn
New Highs: Can CervoMed Inc. stock rebound after recent weaknessJuly 2025 Gainers & Precise Swing Trade Entry Alerts - moha.gov.vn
Pleasing Signs As A Number Of Insiders Buy CervoMed Stock - Yahoo Finance
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2025-12-06 11:12:10 - moha.gov.vn
CervoMed Inc Announces New Data from RewinD-LB Trial - TradingView — Track All Markets
Today's Analyst Rating: CRVO Maintains "Buy" with $31 Price Targ - GuruFocus
Will CervoMed Inc. (DP8) stock benefit from Fed rate cutsJuly 2025 Intraday Action & Daily Volume Surge Signals - Newser
What RSI levels show for CervoMed Inc. (DP8) stockPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - The Manila Times
Why CervoMed Inc. (DP8) stock is a strong analyst pickEarnings Performance Report & Risk Managed Trade Strategies - Newser
Cervomed (CRVO) Unveils Promising Phase 2b Trial Results for Nef - GuruFocus
CervoMed’s DLB drug shows promise in phase 2b trial By Investing.com - Investing.com Nigeria
CervoMed’s DLB drug shows promise in phase 2b trial - Investing.com
CervoMed stock soars after promising dementia drug trial results By Investing.com - Investing.com South Africa
CervoMed stock soars after promising dementia drug trial results - Investing.com
CervoMed Inc. Reports Phase 2b RewinD-LB Trial Results for Neflamapimod, Showing Significant Improvements in Dementia with Lewy Bodies Patients - Quiver Quantitative
CervoMed Announces Late-Breaking Data at the 18th CTAD - GlobeNewswire
How rising interest rates impact CervoMed Inc. stockPortfolio Value Report & Safe Swing Trade Setups - Newser
Is CervoMed Inc. stock attractive after correctionJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser
Why CervoMed Inc. (DP8) stock stays undervaluedM&A Rumor & Short-Term High Return Strategies - Newser
CervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Neflamapimod reduces key neurodegeneration markers in DLB study By Investing.com - Investing.com Canada
CervoMed (NASDAQ:CRVO) Receives Buy Rating from D. Boral Capital - Defense World
Finanzdaten der Cervomed Inc-Aktie (CRVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):